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Two bone graft extenders differing in chemical composition were implanted contralaterally in 
27 consecutive patients undergoing instrumented posterolateral lumbar fusion as standard-
of-care. Bone marrow aspirate and autogenous bone graft were equally combined either 
with β-tricalcium phosphate (β-TCP) or a hybrid biomaterial [containing hyaluronic acid (HyA) 
but lacking a calcium salt] and implanted between the transverse processes. Fusion status 
on each side of the vertebrae was retrospectively graded (1–5 scale) on AP planar X-ray 
at multiple visits as available, through approximately 12 months. Additionally, consolidation 
or resorption since prior visit for each treatment was recorded. Sides receiving β-TCP 
extender showed marked resorption prior to bone consolidation during the first 6 months. 
By contrast, sides receiving the hybrid biomaterial containing integrated HyA showed 
rapid bone consolidation by week 6–8, with maintenance of initial bone volume through 
12 months. Fusion grade was superior for the hybrid biomaterial, differing significantly from 
β-TCP at day 109 and beyond. Fusion success at >12 months was 92.9 vs. 67.9% for the 
hybrid biomaterial and β-TCP-treated sides, respectively. The hybrid biomaterial extender 
demonstrated a shortened time-to-fusion compared to the calcium-based graft. Mode 
of action has been demonstrated in the literature to differ between these compositions. 
Therefore, choice of synthetic biomaterial composition may significantly influence the mode 
of action of cellular events regulating appositional bone growth.
Keywords: bone graft extender, hyaluronic acid, spine fusion, bone marrow aspirate, endochondral ossification, 
biomaterial scaffold
inTrODUcTiOn
Posterolateral spine fusion with pedicle screw stabilization is a common surgical procedure for 
treatment of patients with intractable back pain caused by intervertebral disc degeneration with 
associated spondylolisthesis and/or stenosis. Fusion of the involved spinal segments is achieved by 
bone generation on either side of the vertebral column between the affected transverse processes 
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(gutters) facilitated by placement of bone grafts after decortica-
tion of the transverse processes. It is fundamentally accepted that 
in the absence of added cancellous bone graft (containing viable 
osteoblastic and endothelial elements), the local microenviron-
ment of the posterolateral gutters is challenged in its capacity to 
support large volumes of newly formed bone (1, 2).
Historically, autogenous marrow-rich iliac crest bone graft 
has been the “gold standard” of treatment used to promote bone 
growth in posterolateral fusion because of its proven osteocon-
ductive, osteogenic, and osteoinductive properties (3). However, 
complication rates for this procedure remain high, with donor 
site morbidity related to nerve injury, excessive blood loss, and 
deep wound infection being most commonly reported (4, 5). Of 
more practical importance is the limited volume of iliac crest 
available for multi-level fusion procedures and for individuals in 
whom previous surgeries have been completed. In an attempt to 
either reduce or eliminate dependence on the use of autogenous 
iliac crest bone graft, a variety of synthetic osteoconductive 
extenders have been developed and widely investigated (6, 7). 
While multiple level II studies have demonstrated equivocal 
fusion and clinical outcomes for use of rhBMP-2 with Mastergraft 
in single-level instrumented posterolateral lumbar fusion as a 
substitute for iliac crest bone graft (8–11), recent scrutinization 
of product safety and off-label use questions whether the ben-
efits of rhBMP-2 outweigh its cost and associated patient risks 
(12, 13).
Calcium sulfate and calcium phosphate ceramic bone sub-
stitute materials, including hydroxyapatite and β-tricalcium 
phosphate (β-TCP) or their composites, as well as the bioglasses, 
are widely utilized to minimize or replace the harvest of patient-
derived bone (7, 14–19). While these ceramic-based materials 
were designed to mimic the inorganic phase of native bone, 
inherent disadvantages in their physical properties, variability in 
biochemical characteristics, resorption and bone consolidation 
rates can increase the risk for pseudarthrosis and implant failure 
(19–25). Further, recent in  vitro studies have demonstrated an 
inefficient binding to and retention of human osteoprogenitor 
cells loaded onto a variety of commercially available ceramic-
based products differing in their calcium phosphate chemistries 
(26, 27). It, therefore, remains unknown whether these differ-
ences may ultimately affect the efficacy of ceramic-based bone 
grafts used to extend autogenous bone utilized in posterolateral 
fusion procedures (26).
A hybrid composite of resorbable polymer and natural poly-
saccharide offers predictable, complete replacement by new bone, 
while exhibiting unique biological and physical characteristics 
intended to partner with the body’s own healing potential to fos-
ter bony ingrowth. This novel biomaterial, known as InQu® Bone 
Graft Extender & Substitute, has proved clinically effective in pos-
terior interbody lumbar fusion procedures (28), in addition to the 
successful treatment of long bone defects (Harris and Adkisson, 
in preparation) and the reconstruction of high-risk foot and 
ankle deformities secondary to diabetes (Charcot reconstruc-
tion; Kerzner, in preparation). The hybrid biomaterial provides 
a compressive resistant, porous osteoconductive scaffold made 
of poly (d, l-lactide-co-glycolide), within which hyaluronic acid 
(HyA) is entangled. To date, no clinical study has explored the 
safety and effectiveness of this radiolucent extender to promote 
lumbar posterolateral arthrodesis.
The purpose of the present retrospective clinical case series 
was to compare fusion grade and consolidation/resorption 
characteristics of two commercially cleared synthetic bone 
graft substitute devices utilized within the same patients, per 
physician discretion, on opposite sides of the fusion construct 
as autograft extenders for instrumented posterolateral lumbar 
fusion. Additionally, a time-to-fusion analysis between these 
two products was evaluated. It was hypothesized that differences 
in biomaterial composition may reveal differences in the rate at 
which new bone was formed.
MaTerials anD MeThODs
study Design
This is a single center, non-randomized, case series comprising 27 
consecutive patients having undergone single- and/or multi-level 
posterolateral lumbar fusions with segmental spinal instrumenta-
tion utilized bilaterally. A retrospective data collection effort to 
assess radiographic outcomes conducted under IRB oversight 
(waiver of consent) was requested of the Western Institution 
Review Board (WIRB) and approved. No additional clinical 
outcomes were assessed as part of this study.
Surgeries were performed between September 2008 and May 
2009 in which InQu® (ISTO Technologies, St. Louis, MO, USA) 
and β-TCP (TheriGraft® TCP Putty Bone Void Filler, Therics, 
LLC, Princeton, NJ, USA) were applied contralaterally as auto-
graft extenders per physician discretion as described below. This 
was a standard-of-care approach to spine fusion utilizing two 
devices with 510k clearances in association with pedicle screw 
stabilization. Radiographic follow-up standard-of-care included 
anterior/posterior X-rays at various intervals post-surgery to 
15 months. Because computed tomography (CT) was not medi-
cally necessary for any of the study subjects, no CT exams were 
ordered as part of clinical radiographic follow-up.
Patient Demographics
The study population encompassed 27 subjects (18 males; 9 females) 
averaging 62.7 years of age (range, 26–86 years; median 67 years). 
No subjects were excluded from analysis. All comorbidities were 
recorded, including fusion risk factors and patient diagnoses prior 
to surgery. One subject received treatment at two different con-
tiguous fusion levels of the vertebrae; thus, data for 28 contiguous 
fusion levels and 56 distinct fusion segments were captured.
surgery
Local bone removed from the laminae and spinous processes in 
the region of spinal canal stenosis was morcelized and split equally 
between treatment sides after meticulous removal of covering 
soft tissues. Approximately 10 cc of posterior iliac crest was then 
harvested and similarly morcelized and divided among treatment 
sides. Next, 10  cc of graft extender (either InQu or TCP) was 
mixed with 6 cc of bone aspirate harvested from the posterior iliac 
crest and immediately applied to morcelized bone (obtained from 
the iliac crest and locally). Once stabilization of the target level(s) 
FigUre 1 | examples of fusion grade definition.
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was completed using transpedicular screw/rod instrumentation 
with cross-links, decortication of the transverse processes was 
performed. Equivalent amounts of the final extender construct 
were placed on either side of the posterolateral gutters – β-TCP 
on the left and InQu hybrid biomaterial on the right. All surgical 
procedures were performed per the surgeon’s routine standard 
care. If spondylolisthesis was present, no forceful reduction was 
attempted. If circumferential fusion was indicated (n = 16), only 
iliac crest bone graft was used within the interbody fusion device. 
No additional graft material was placed anterior to the cage. 
Patients were seen for routine follow-up assessment and anterior/
posterior (A/P) and lateral radiographs as per the standard-of-
care, usually at approximate intervals of 2  weeks after surgery 
(baseline), 3, 6, and 12 months. These post-operative radiographs 
were collected between 9/18/2009 and 7/22/2010.
Outcomes
The physician read each of the radiographs (unblinded) and 
recorded his fusion assessment using a fusion grade scale. Each 
fusion side (the whole contiguous fusion segment whether multi-
level or single-level fusion) was evaluated separately for fusion 
grade (5 = Definitely fused; 4 = Probably fused; 3 = Indeterminate; 
2 =  Probably not fused; 1 =  Definitely not fused) (Figure  1). 
Sequential radiographs were graded for graft consolidation/resorp-
tion as compared with the prior visit. Demographic and baseline 
data were tabulated and summarized for the whole population.
statistics
The first primary outcome measure determined the difference in 
fusion grades between treatment type over time using a mixed 
model, repeated measures, covariate analysis in SAS (SAS Institute, 
Inc., Cary, NC, USA). Once the final model was determined, a 
predicted regression line over time was developed for each treat-
ment. Predicted mean fusion grade difference between treatments 
over time was compared statistically and represented graphically.
The second assessment tabulated fusion for each treatment 
type at various post-operative time intervals. This was performed 
by comparing percentages of fusions categorized as “probably/
definitely” fused, “indeterminate,” and “probably/definitely” not 
fused at defined time intervals: days 21–90; 91–180; 181–360; and 
>360. A “last observation carried forward” procedure was used 
to impute missing fusion rates. Statistical comparisons between 
treatments were performed using the Friedman Chi-square Test 
at each time interval and for the overall interval.
The third primary assessment was a Kaplan–Meier time-
to-fusion analysis conducted for both treatments. Time to first 
“Probably/Definitely” fused (fusion grade of 4 or 5) was computed 
for each fusion segment using the Kaplan–Meier estimate for 
each treatment. The median time-to-fusion was estimated across 
time (days to fusion) for each bone graft extender. The treatment 
curves were compared. Fusion segments (grades 1–3) that never 
completely fused >360 days were considered treatment failures.
A secondary outcome measure was radiologic consolidation/
resorption of the fusion construct. Consolidation since prior visit 
was graded as an increase (+1 increment); resorption since prior 
visit as a decrease (−1 decrement); and no change since prior visit 
was graded as zero. These values were added sequentially for plot-
ting purposes. The value at each assessment was added to the prior 
assessment, and the values were plotted on a graph separately for 
each fusion segment for both treatments. The trends were pro-
vided graphically descriptively without statistical analyses.
resUlTs
Demographics and Baseline
Twenty-seven subjects comprising 28 contiguous treatment levels 
(bilateral segments), and thus 56 distinct individual fusion seg-
ments, were identified and their data were collected retrospectively 
in case report forms by site personnel. This cohort represented a 
case series of consecutive patients requiring lumbar arthrodesis, 
and therefore included a heterogeneous mix of patients with 
respect to general health status, number of levels fused and 
concurrent use of interbody spacers. Fusion levels within each 
bilateral segment ranged from 1 to 6 levels. One subject had two 
TaBle 3 | Baseline co-morbid chronic diseases.
comorbidities number subjects (%)
N = 27
DiaBeTes
Yes  9 (33.3%)
No 18 (66.7%)
cOrOnarY arTerY Disease (caD)
Yes  8 (29.6%)
No 19 (70.4%)
chrOnic OBsTrUcTiVe PUlMOnarY Disease (cOPD)
Yes 2 (7.4%)
No 25 (92.6%)
chrOnic renal FailUre
Yes 0 (0.0%)
No 27 (100.0%)
sTerOiDs Use
Yes 0 (0.0%)
No 27 (100.0%)
nsaiDs Use
Yes 0 (0.0%)
No 27 (100.0%)
NSAIDs, non-steroidal anti-inflammatory drug.
TaBle 2 | Baseline patient demographics.
Baseline variable number subjects (%)
N = 27
genDer
Male 19 (70.4%)
Female 8 (29.6%)
BMi
≤30 18 (66.7%)
>30 9 (33.3%)
age
≤60 years 8 (29.6%)
>60 ≤ 70 years 13 (48.1%)
>70 years 6 (22.2%)
sMOKer
Yes 2 (7.4%)
No 25 (92.6%)
Fusion segments
N = 28a
nUMBer OF FUsiOn leVels
Single 7 (25.0%)
Double 16 (57.1%)
3+ levels 5 (17.9%)
Body mass index (BMI) of 18.5–24.9 is considered normal weight; BMI of 25–29.9 is 
considered overweight; BMI of 30 and above is considered obese. http://en.wikipedia.
org/wiki/Body_mass_index
aOne subject had two fusion levels that were not contiguous; each fusion segment in 
this subject was evaluated separately.
TaBle 1 | Posterolateral (Pl) fusion levels and concurrent interbody (iB) 
fusions.
number of 
patients
number of Pl fusion 
levels
number of concurrent iB 
levels
1 1 0
7 2 0
1 3 0
2 4 0
5 1 1
4 2 2
5 2 1
1 4 1
1 6 1
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bilateral segments treated that were non-contiguous (L2-3 and 
L5-S1). Each treated segment was evaluated separately. Therefore, 
a total of 28 bilateral fusion segments or 56 individual fusion 
segments were evaluated. All fusions utilized pedicle screws 
and rods with cross-links. Sixteen subjects (59.2%) underwent 
concurrent posterior interbody fusion at one or more levels with 
posterolateral fusion in this study (Table 1).
The demographics and baseline characteristics are identical 
for both treatments (Table 2). Mean age of the population was 
62.7  years (range 26–86, SD, 13.44  years). The subjects were 
primarily male (70.4%), non-smokers (92.6%), and recipients of 
two-level fusions (57.1%). The population was generally over-
weight by US standards with a mean BMI of 29.52 (range 22.3–41, 
median 27.8), but one-third of the population was considered 
obese.
Baseline co-morbid chronic diseases potentially affecting 
arthrodesis were collected and tabulated (Table 3). The popula-
tion was predominantly free of risk factors affecting bone heal-
ing: 66.7% were without diabetes; 92.6% were without chronic 
obstructive pulmonary disease (COPD); and 70.4% were without 
coronary artery disease. No patients reported chronic renal 
disease or steroid use. Non-steroidal anti-inflammatory drugs 
(NSAIDs) were discouraged prior to surgery until 6 months after 
surgery. Only two patients were recorded as chronic tobacco 
users and nine were recorded as receiving treatment for diabetes.
Concomitant spinal diagnoses are presented in Table  4. 
Patients in this study were undergoing decompressive laminec-
tomy and posterolateral lumbar fusion for spinal stenosis (88.9%), 
herniated nucleus pulposus (22.2%), or both. Concomitant spinal 
diagnoses included spondylolisthesis (37%); degenerative disc 
disease (22.2%); prior laminectomy (11.1%); pseudarthrosis 
(3.7%); and scoliosis (3.7%).
analysis of Predicted Mean Fusion grade 
Differences Over Time
Fusion was assessed for each (left and right) posterolateral 
contiguous fusion segment according to the graft extender used 
(n = 28 InQu treated; n = 28 β-TCP treated). Fusion grade scores 
were examined with a repeated measures regression analysis with 
several covariates, including number of levels treated, days from 
surgery, subject age, gender, BMI, and comorbidities to fusion 
(tobacco use, diabetes, COPD, spondylolisthesis, herniated disc, 
DDD). Only “treatment by days from surgery” was a significant 
factor. This interaction was explored (Figures 2 and 3) by com-
paring the treatment’s predicted mean fusion grade responses at 
selected time points that spanned the days from surgery. Although 
during the initial healing phase (<day 109) the predicted mean 
TaBle 4 | concomitant spinal diagnoses.
concomitant spine diagnoses number patients (%)
N = 27
sPinal sTenOsis
Yes 24 (88.9%)
No 3 (11.1%)
sPOnDYlOlisThesis
Yes 10 (37.0%)
No 17 (63.0%)
herniaTeD nUcleUs PUlPOsUs
Yes 6 (22.2%)
No 21 (77.8%)
Disc DegeneraTiOn
Yes 6 (22.2%)
No 21 (77.8%)
scOliOsis
Yes 1 (3.7%)
No 26 (96.3%)
POsT-laMinecTOMY
Yes 3 (11.1%)
No 24 (88.9%)
PseUDOarThrOsis
Yes 1 (3.7%)
No 26 (96.3%)
FigUre 2 | Predicted mean differences with 95% confidence intervals. From day 109 forward, the predicted mean fusion grade (grade 4 probably fused/
grade 5 definitely fused) for segment receiving InQu extender was found to be statistically significantly (p < 0.05) better than the predicted mean for those sides 
receiving β-TCP extender.
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fusion grades for the InQu-treated side were greater than that for 
the β-TCP-treated side, statistically significant differences were 
not experienced. However, from day 109 forward, the predicted 
mean fusion grade for InQu was found to be statistically signifi-
cantly (p < 0.05) greater than the predicted mean for β-TCP.
Fusion assessment at Various 
Time intervals
Fusion rates were assessed at four time periods (Table 5). A last 
observation carried forward procedure was used to impute miss-
ing rates. Due to fragmentation of the small sample size across five 
categories that dilute the analysis, “Definitely Fused”/“Probably 
Fused” were collapsed into a single category, “Fused”; similarly, 
“Definitely Not Fused”/“Probably Not Fused” were collapsed 
into – “Not Fused.” When comparing the fusion outcomes across 
all time intervals using the Friedman (Chi-Square) test, statistically 
significant overall differences (p < 0.0031) were observed. A higher 
percentage of InQu-treated fusion segments demonstrated suc-
cessful fusion results than β-TCP-treated fusion segments. By days 
181–360, the significant difference (p < 0.05) was 75% fused (InQu) 
vs. 50% fused (β-TCP); and for days >361, the significant difference 
was 92.9% fused (InQu) vs. 67.9% fused (β-TCP) (p < 0.02).
Two subjects were not fused on both the β-TCP-treated and 
the InQu-treated segments. Zero segments were not fused on 
the InQu-treated side only, whereas seven segments were not 
fused on the β-TCP-treated side only. Of the two subjects that 
did not fuse on either side, one was treated from T12-S1 and the 
fusion was graded as 3 – Indeterminate – at the last visit recorded, 
almost 1-year post-operative. In the same subject at that visit, 
the InQu-treated side showed increasing consolidation, but the 
β-TCP side showed increasing resorption since prior visit. The 
second subject with fusion failure on both sides was graded a 
3 – Indeterminate – on both sides, with increasing consolidation 
observed for both treatments at 5 months, the last recorded visit.
Of the 11 subjects identified as either active smokers or hav-
ing diabetes, no fusion failures were noted for either treatment. 
TaBle 5 | Fusion assessment outcomes by time interval.
Treatment assessment Days 21–90 Days 91–180 Days 181–360 Days >361
InQu, n = 28 Not fused 26 (92.6%) 8 (28.6%) 2 (7.1%) 0 (0.0%)
Indeterminate 1 (3.6%) 11 (39.3%) 5 (17.9%)  2 (7.1%)
Fused 1 (3.6%) 9 (32.1%) 21 (75.0%) 26 (92.9%)
TCP, n = 28 Not fused 25 (89.3%) 11 (39.3%) 6 (21.4%) 3 (10.7%)
Indeterminate 2 (7.1%) 13 (46.4%) 8 (28.6%) 6 (21.4%)
Fused 1 (3.6%) 4 (14.3%) 14 (50.0%) 19 (67.9%)
Generalized overall Friedman (Chi-Square) Test
Value, p-value Value, p-value Value, p-value Value, p-value
0.10, 0.7555 2.00, 0.1568 3.96, 0.0465 5.95, 0.0147
Value, p-value
8.75, 0.0031
FigUre 3 | Kaplan–Meier analysis of time-to-fusion. The log-rank test of the homogeneity of the Kaplan–Meier curves showed that the time-to-fusion for the 
InQu-treated side at 206 days was significantly (p < 0.0309) shorter than the β-TCP curve at 318 days.
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However, in four fusion segments (three patients) receiving β-
TCP extender, an “Indeterminate” fusion (Grade 3) was recorded. 
The opposite side receiving InQu extender in these patients 
presented radiographically as “Probably Fused” (Grade 4) in four 
segments, with the last being “Indeterminate” (Grade 3) and was 
not considered statistically significantly different.
Time-to-Fusion analysis
The results of the Kaplan–Meier analysis of Time-to-Fusion 
are displayed in Table 6 and illustrated in Figure 3. Using the 
collapsed categories of Fused, Indeterminate, and Not fused, a 
“worst-case” scenario counted all “Indeterminate” assessments 
as fusion failures. Comparison of the fusion assessment showed 
that the InQu-treated segments fused significantly faster than 
the β-TCP-treated sides. The estimated median Time-to-Fusion 
for InQu and β-TCP were 206 and 318  days, respectively 
(p < 0.0309).
graft resorption/consolidation 
assessment
Graphical analysis of graft resorption/consolidation (as described 
previously) was plotted as the format of the data did not lend 
itself to statistical analysis. The plots show graphically the dif-
ferences between treatment sides. For sides receiving InQu 
extender (Figure  4A), all the lines lie in the upper half of the 
graph, demonstrating that there is no significant initial resorptive 
phase, only intervals of increasing consolidation over time. Prior 
to day 90, most of the lines are flat, demonstrating that there is 
no radiographically observable difference from surgery. Not only 
is InQu radiolucent, but also cartilage growth – an early step in 
InQu’s mechanism of action “endochondral ossification” – is not 
easily observed radiographically on plain films. However, bony 
consolidation is observable on plain radiographs concurrently 
with cartilage calcification and formation of woven bone. Between 
days 91 and 135, all the InQu fusion segment lines showed a steady 
TaBle 6 | Time-to-fusion.
characteristic statistics inQu TcP
Time-to-first probably/
definitely fused (days)
N 28 28
n (fusion) 26 19
N (no fusion) 2 9
Median days to first fusiona 206 318
25th percentilea 14 192
75th percentilea 355 402
Log-rank test 4.6561
p-valueb 0.0309
aThe median, 25th percentile, and 75th percentile are estimated from Kaplan–Meier 
survival curve.
bp-value calculated based on Chi-Square (1 degree of freedom).
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increase, and progressive consolidation was generally observed to 
360 days and beyond.
For sides receiving β-TCP extender (Figure  4B), a differ-
ent picture was observed that is consistent with the β-TCP 
mechanism of action. A flat line demonstrates for most of the 
β-TCP fusion segments between days 91 and 135, no change in 
radiographic appearance from surgery. Given the high radio-
graphic signal intensity of β-TCP, it is difficult to estimate graft 
consolidation with surrounding tissue until the mineral content 
has been cleared by osteoclastic activity and replaced by new 
bone. Once complete, an increase in the height of the plotted lines 
(consolidation) was observed for one or more time intervals in 
21 of 28 fusion segments. However, from day 135 and forward, 
seven of 28 fusion segments (25%) showed a steady decline in line 
height toward the negative portion of the graph, indicating that 
more resorption had occurred than consolidation. A representa-
tive example of this resorption phase, identified only for sides 
receiving β-TCP extender, is illustrated in Figure 5. In this subject 
(46 year-old female with diabetes) sequential radiographs docu-
ment marked resorption of implanted β-TCP between weeks 2 
and 24, whereas the contralateral side receiving hybrid extender 
demonstrated radiographic evidence of consolidation as early as 
week 6 post-treatment.
There were only a limited number of actual data points at days 
>360; the rest of the data at this time point were imputed in a 
last-observation-carried-forward (LOCF) analysis. It is unclear 
if an actual plateau had been attained for each patient in either 
treatment group or whether one or both groups would continue 
to consolidate further.
safety
Two adverse events were identified in this patient sample upon 
radiographic review of day 270–360 radiographs. One patient 
had radiographic evidence of a fractured screw, although fusion 
appeared solid. The second patient developed a large synovial cyst 
at an adjacent level with neurocompression; the patient was sub-
sequently treated with surgical decompression and instrumented 
fusion. In the latter case, surgical exploration of the fusion seg-
ment confirmed solid fusion. No serious adverse events relating 
specifically to the use of β-TCP or InQu were reported during 
the study.
DiscUssiOn
Bone graft substitutes are commonly used to extend the volume 
of available autogenous bone harvested in major reconstructive 
spine procedures (7, 15). While ceramic-based osteoconductive 
scaffolds account for a majority of the synthetic bone substitute 
materials, it is unclear whether inorganic mineral is essential 
for  –  or contributes favorably to  –  bone formation. Preclinical 
studies have shown that persistence of hydroxyapatite contain-
ing grafts may interfere with progressive bone formation (20, 
21). Similarly, too rapid resorption of calcium sulfate (20, 24) 
and fragmentation of partially resorbed β-TCP may be associ-
ated with failed arthrodesis both in animals and man (20, 29). 
Further, Hsu et  al. (26) and Murphy et  al. (27) independently 
demonstrated unfavorable biocompatibility characteristics for a 
variety of ceramic-based bone graft substitutes with respect to cell 
binding, retention, and proliferation. It was concluded that only 
osteoconductive scaffolds, which allow for high rates of preosteo-
blast adhesion, cell survival, and proliferation may be expected to 
yield the most predictable, effective clinical performance.
The present study retrospectively compared overall fusion suc-
cess of a β-TCP ceramic bone graft and a novel non-ceramic bio-
synthetic scaffold-containing integrated HyA. These 510k cleared 
devices were evaluated side-by-side in a series of patients requiring 
instrumented posterolateral lumbar fusion. Plain film radiographic 
assessment was used to grade posterolateral fusion over time. 
These data were assessed for predicted mean differences between 
treatments over time using a mixed model, repeated measures 
covariate analysis, which demonstrated statistically significantly 
higher fusion grades for InQu extender over β-TCP extender at day 
109 and beyond. Additionally, Kaplan–Meier analysis of Time-to-
Fusion demonstrated a substantial time advantage (112 days faster) 
in the assimilation and fusion process for those segments receiving 
InQu over β-TCP. The radiographic description of resorption/
consolidation between assessment windows revealed that 25% of 
the β-TCP segments failed to trend toward consolidation, whereas 
all segments receiving the hybrid polymer demonstrated consoli-
dation at one or more assessment windows, even in eight of nine 
(88.9%) subjects receiving clinical treatment for diabetes.
The mechanism of bone formation supported by the applica-
tion of InQu to osseous defects has been reported previously. 
Histological assessment of healing for cancellous metaphyseal 
defects of the distal femur in rabbits presented clear evidence for 
endochondral bone growth via the migration and differentiation 
of mesenchymal stem cells from surrounding bone marrow (30). 
At 3 months, the porous structure of InQu was replaced by calcified 
cartilage and newly woven bone, which by 6 months had remod-
eled to form mature lamellar bone. Histological observation of 
sham defects in rabbits revealed an abnormal fatty appearance to 
the marrow space occupying these defects, with a futile attempt 
at revascularization. Further confirmation of this mechanism of 
action was recently obtained in the Boden model for posterolat-
eral lumbar fusion using a mixture of InQu granules and ICBG 
(50:50 ratio) (31). Vascularization of a cartilage intermediate was 
accompanied histologically by calcification of the cartilage matrix, 
which ultimately was replaced by woven bone from invading 
FigUre 4 | (a) InQu resorption/consolidation assessment by subject over time. Each line lies in the upper half of the graph demonstrating that there is no significant initial 
resorptive phase, only intervals of increasing consolidation over time. (B) β-TCP resorption/consolidation assessment by subject over time. A flat line demonstrates for 
most of the β-TCP-treated fusion segments between days 91–135 no change in radiographic appearance from surgery. Once the mineral content has been cleared, an 
increase in the height of the plotted lines (consolidation) was observed for one or more time intervals in 21 of 28 fusion segments. However, from day 135 and on, 7 of 28 
fusion segments (25%) showed a steady decline in line height toward the negative portion of the graph, indicating that more resorption had occurred than consolidation.
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FigUre 5 | comparative radiography depicting resorption and consolidation of two bone graft extenders. A 46-year-old female with history of active 
tobacco use and diabetes underwent PL fusion of the lumbar spine at L2-3 and L5-S1. AP radiographs at L2-3 are shown over time. Left side received bone 
autograft, BMA, and β-TCP putty. Right side received equal mix of bone autograft, BMA, and InQu putty. Sequential assessment over 24 weeks illustrates marked 
resorption of ceramic bone graft, whereas the opposite side receiving hybrid extender showed consolidation of applied graft at 6 weeks, with sustained bone 
volume at 24 weeks.
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osteoprogenitor cells originating from the vasculature (31). It is 
noteworthy that the formation of cartilagenous matrix does not 
lend itself to radiographic characterization before it has under-
gone terminal differentiation through bony replacement. Fusion 
(Grade 4/5) in the present study was generally first observable 
for the InQu-treated fusion segments at day 206, but not until 
day 318 for the β-TCP-treated fusion segments, and ultimately, 
the degree of fusion success at >day 360 was much higher in the 
InQu-treated group (92.6% InQu vs. 67.9% β-TCP, p < 0.02).
The absorption and bony replacement of β-TCP-based grafts 
involves a biologically distinct mechanism whereby osteoclasts, 
formed through macrophage fusion, adhere to the β-TCP sur-
face to remove mineral in preparation of osteoblast adherence 
and the deposition of newly mineralized bone matrix (20, 22, 
32). Histological review of the in vivo resorption characteristics 
of β-TCP implanted into osteochondral defects in rabbits sug-
gested that osteoclastic resorption and fragmentation of the 
osteoconductive scaffold minimized the volume of regenerated 
bone (20). This observation of a loss of template bone volume is 
consistent with a previous report by Hollinger et al. (33), placing 
into question whether β-TCP-based bone grafts should be used 
as extenders in reconstructive spine procedures where large 
volumes of new bone are required to stabilize implant hardware. 
Radiographs from the present study captured the resorption of 
β-TCP extender as a reduction in radiographic intensity, which 
appeared as early as 6–12  weeks postoperatively. Interestingly, 
this resorption process progressed further in a handful of cases 
to reflect a significant loss of bone volume between months 6 
and 12 of follow-up. Extensive graft resorption accompanied by 
limited production of new bony ingrowth has the disadvantage of 
providing poor stability to the fusion segment, which could lead 
to future complications requiring intervention.
Other potential disadvantages to the use of ceramic bone graft 
substitutes for spine fusion are their reported friability, low impact 
resistance (19, 22), and the radiographic challenge posed by their 
intrinsic radiopacity (34). By contrast, InQu is radiolucent and per-
mits progressive visualization on plain film X-ray of the incorpora-
tion/consolidation of newly formed bone. Furthermore, it should be 
emphasized that InQu-treated segments appeared radiographically 
to either maintain or increase their initial bone volume with fusion 
progression. This observation suggests that InQu provides a stable 
porous structure that retains its bulking properties under compres-
sion in the posterolateral gutters. Unlike ceramic bone grafts, the 
backbone structure of InQu (PLGA) biodegrades through random 
hydrolytic scission of ester bonds, independently of cellular activity 
(33, 35, 36). Preclinical studies have demonstrated a tissue residence 
time of 3–6 months for InQu granules that were mixed equally with 
ICBG for posterolateral lumbar fusion (31).
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The role of HyA in embryonic development and general 
wound healing is well recognized (37–39). However, few studies 
have explored the potential contribution of HyA to bone healing 
and remodeling (39–41). Sasaki and Watanabe (39) were the first 
to report the healing effect of HyA on bone growth in rats using a 
bone marrow ablation model (39). Importantly, HyA is reported 
to support renewal of hematopoietic stem cells by increasing 
cytokine production (42). In line with these results, Sasaki and 
Watanabe presented histological evidence for normal recon-
stitution of marrow cavities in half the time observed for sham 
controls (saline), following the administration of high-molecular 
weight HyA (39). CD34+ endothelial progenitor cells may play a 
critical role in revascularization following bone marrow ablation 
injury and treatment with HyA. This hypothesis is supported by 
the recent findings of Raines et  al. (40), who reported neovas-
cularization by exogenous high-molecular weight HyA following 
bone marrow ablation in rats. Additional studies have reported 
that scaffolds created from chemically modified HyA enhance 
mesenchymal stem cell binding and yield greater quantities of 
new bone in osteochondral defects created in the rabbit knee 
when compared to defects receiving resorbable PLGA scaffolds 
alone (43, 44). Solchaga et al. (43, 44) found that tissue-engineered 
scaffolds made from HyA supported endochondral ossification, 
recapitulating embryologic events recognized to mediate long 
bone growth and fracture repair. In light of these findings, it is 
speculated that the hybrid biomaterial (InQu) used in the present 
clinical study supports bone regeneration by creating a local 
environment conducive to the attachment, proliferation, and 
differentiation of the body’s own stem cells. Both endothelial and 
osteogenic progenitor cells retain specific cell surface receptors for 
HyA, which mediate cell survival, proliferation, and differentiation 
(38, 45–47), through which cell-receptor coupling may contribute 
to the shortened time-to-fusion borne out by the current data.
Several weaknesses of the study should be mentioned. This 
was a retrospective study in a small patient group in a clinical 
practice setting, and not a research setting. Both graft extenders 
were commercially available and utilized at the sole discretion of 
the attending physician. Data collection was performed according 
to physician’s standard-of-care. Therefore, neither special meas-
ures of 3-D CT reconstruction were performed nor were clinical 
outcomes data pertaining to pain and function collected via a 
validated instrument. While evaluations (radiological assessment 
of fusion and resorption/consolidation) were performed by the 
attending physician (GS) in an unblinded fashion, this physician 
has >20  years of experience assessing radiological outcomes 
for spinal arthrodesis. Future prospective studies utilizing ran-
domization, blinding, more objective radiographic criteria, and 
clinical outcomes measures will present stronger support for 
the differences observed. Despite these study limitations, these 
data provide compelling evidence to suggest that a new hybrid 
osteoconductive bone graft, lacking calcium-based salts, may 
support rapid progression of bony fusion through endochondral 
ossification, even in patients with comorbidities to arthrodesis.
cOnclUsiOn
Synthetic biomaterials utilized for spinal fusion procedures differ 
in composition and are often chosen by surgeons based upon 
handling characteristics. The present study compared two 510k 
cleared bone grafts utilized as extenders for posterolateral fusion 
in a series of 27 subjects where multiple radiographs obtained over 
the course of 15 months enabled side-by-side comparison of the 
radiographic appearance of each construct, with patients serving 
as their own control. Fusion success at the >12-month interval 
for sides receiving the radiolucent hybrid biomaterial, designed 
to support endochondral ossification, was statistically superior 
(p = 0.015) to contralateral sides receiving β-TCP. Given that each 
treatment side received similar quantities of autograft in the form 
of local bone, bone marrow aspirate and iliac crest, the observed 
treatment effect is surprising. Physicians must consider bone graft 
composition, biocompatibility, and more importantly mode of 
action in their decision to utilize specific biomaterial scaffolds. 
This concept becomes increasingly important when bone grafts 
are utilized as delivery vehicles for autologous cell therapies.
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